Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Editorial: Cardiovascular Disease Mortality Rates are Plateauing in Certain Age Groups and Regions. Can we Keep them Declining?.
Curr Vasc Pharmacol. 14(3), 271-4.
(2016). Antisense technology for the prevention or the treatment of cardiovascular disease: the next blockbuster?.
Expert Opin Investig Drugs. 17(7), 969-72.
(2008). Cardiovascular benefits of bariatric surgery in morbidly obese patients..
Obes Rev. 12(7), 515-24.
(2011). Relation of improvement in glomerular filtration rate with atorvastatin to reductions in heart failure morbidity..
Am J Cardiol. 110(5), 763.
(2012). Preventing Cardio-renal Syndrome Rather than Treating It: Could Statins Play A Role?.
Open Cardiovasc Med J. 5, 226-30.
(2011). IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis..
Arch Med Sci. 7(6), 984-92.
(2011). Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update..
World J Gastroenterol. 21(22), 6820-34.
(2015). Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?.
Expert Opin Pharmacother. 8(14), 2267-77.
(2007). Off target effects of statins shape total mortality?.
J Drug Assess. 5(1), 4-5.
(2016). Nonalcoholic fatty liver disease and severity of cardiovascular disease manifestations..
Angiology. 64(8), 572-5.
(2013). Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment..
Open Cardiovasc Med J. 5, 24-34.
(2011). Statins and heart failure..
J Am Coll Cardiol. 55(15), 1644-5; author reply 1646.
(2010). The clinical benefit of implementing guidelines in cardiovascular disease prevention in real world settings..
Arch Med Sci. 8(1), 6-10.
(2012). Statins for the prevention of first or recurrent stroke..
Curr Vasc Pharmacol. 6(2), 124-33.
(2008). Comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property"..
Dig Liver Dis. 45(1), 82-3.
(2013). Statin treatment may be beneficial to both the kidneys and the heart..
Perit Dial Int. 27(2), 215-6.
(2007).
(2017). Genetic, epidemiologic and clinical data strongly suggest that fasting or non-fasting triglycerides are independent cardiovascular risk factors..
Curr Med Res Opin. 31(3), 435-8.
(2015). Effect of a plant stanol ester-containing spread, placebo spread, or Mediterranean diet on estimated cardiovascular risk and lipid, inflammatory and haemostatic factors..
Nutr Metab Cardiovasc Dis. 21(3), 213-21.
(2011). Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy..
Expert Opin Pharmacother. 11(5), 723-30.
(2010). The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Metabolism. 71, 17 - 32.
(2017). Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients..
Am J Cardiol. 101(4), 483-5.
(2008). Statins and cardiovascular events in patients with end-stage renal disease on hemodialysis. The AURORA results suggest the need for earlier intervention..
Curr Vasc Pharmacol. 7(3), 264-6.
(2009).
(2013).
(2019).